Iodine-131 (131I) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because I-131 is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission (by weight). See fission product yield for a comparison with other radioactive fission products. I-131 is also a major fission product of uranium-233, produced from thorium.
Due to its mode of beta decay, iodine-131 is notable for causing mutation and death in cells that it penetrates, and other cells up to several millimeters away. For this reason, high doses of the isotope are sometimes less dangerous than low doses, since they tend to kill thyroid tissues that would otherwise become cancerous as a result of the radiation. For example, children treated with moderate dose of I-131 for thyroid adenomas had a detectable increase in thyroid cancer, but children treated with a much higher dose did not. Likewise, most studies of very-high-dose I-131 for treatment of Graves disease have failed to find any increase in thyroid cancer, even though there is linear increase in thyroid cancer risk with I-131 absorption at moderate doses. Thus, iodine-131 is increasingly less employed in small doses in medical use (especially in children), but increasingly is used only in large and maximal treatment doses, as a way of killing targeted tissues. This is known as "therapeutic use."
Iodine-131 can be "seen" by nuclear medicine imaging techniques (i.e., gamma cameras) whenever it is given for therapeutic use, since about 10% of its energy and radiation dose is via gamma radiation. However, since the other 90% of radiation (beta radiation) causes tissue damage without contributing to any ability to see or "image" the isotope, other less-damaging radioisotopes of iodine such as iodine-123 (see isotopes of iodine) are preferred in situations when only nuclear imaging is required. The isotope I-131 is still occasionally used for purely diagnostic (i.e., imaging) work, due to its low expense compared to other iodine radioisotopes. Very small medical imaging doses of I-131 have not shown any increase in thyroid cancer. The low-cost availability of I-131, in turn, is due to the relative ease of creating I-131 by neutron bombardment of natural tellurium in a nuclear reactor, then separating I-131 out by various simple methods (i.e., heating to drive off the volatile iodine). By contrast, other iodine radioisotopes are usually created by far more expensive techniques, starting with reactor radiation of expensive capsules of pressurized xenon gas.
Iodine-131 is also one of the most commonly used gamma-emitting radioactive industrial tracer. Radioactive tracer isotopes are injected with hydraulic fracturing fluid to determine the injection profile and location of fractures created by hydraulic fracturing.
Much smaller incidental doses of iodine-131 than those used in medical therapeutic procedures, are supposed by some studies to be the major cause of increased thyroid cancers after accidental nuclear contamination. These studies suppose that cancers happen from residual tissue radiation damage caused by the I-131, and should appear mostly years after exposure, long after the I-131 has decayed. Other studies can't find a correlation.
Video Iodine-131
Production
Most I-131 production is from nuclear reactor neutron-irradiation of a natural tellurium target. Irradiation of natural tellurium produces almost entirely I-131 as the only radionuclide with a half-life longer than hours, since most lighter isotopes of tellurium become heavier stable isotopes, or else stable iodine or xenon. However, the heaviest naturally occurring tellurium nuclide, Te-130 (34% of natural Te) absorbs a neutron to become tellurium-131, which beta-decays with a half-life of 25 minutes, to I-131.
A tellurium compound can be irradiated while bound as an oxide to an ion exchange column, and evolved I-131 then eluted into an alkaline solution. More commonly, powdered elemental tellurium is irradiated and then I-131 separated from it by dry distillation of the iodine, which has a far higher vapor pressure. The element is then dissolved in a mildly alkaline solution in the standard manner, to produce I-131 as iodide and hypoiodate (which is soon reduced to iodide).
131I is a fission product with a yield of 2.878% from uranium-235, and can be released in nuclear weapons tests and nuclear accidents. However, the short half-life means it is not present in significant quantities in cooled spent nuclear fuel, unlike iodine-129 whose half-life is nearly a billion times that of I-131.
It is discharged to the atmosphere in small quantities by some nuclear power plants.
Maps Iodine-131
Radioactive decay
I-131 decays with a half-life of 8.02 days with beta minus and gamma emissions. This nuclide of iodine has 78 neutrons in its nucleus, while the only stable nuclide, 127I, has 74. On decaying, 131I most often (89% of the time) expends its 971 keV of decay energy by transforming into the stable 131Xe (Xenon) in two steps, with gamma decay following rapidly after beta decay:
The primary emissions of 131I decay are thus electrons with a maximal energy of 606 keV (89% abundance, others 248-807 keV) and 364 keV gamma rays (81% abundance, others 723 keV). Beta decay also produces an antineutrino, which carries off variable amounts of the beta decay energy. The electrons, due to their high mean energy (190 keV, with typical beta-decay spectra present) have a tissue penetration of 0.6 to 2 mm.
Effects of exposure
Iodine in food is absorbed by the body and preferentially concentrated in the thyroid where it is needed for the functioning of that gland. When 131I is present in high levels in the environment from radioactive fallout, it can be absorbed through contaminated food, and will also accumulate in the thyroid. As it decays, it may cause damage to the thyroid. The primary risk from exposure to high levels of 131I is the chance occurrence of radiogenic thyroid cancer in later life. Other risks include the possibility of non-cancerous growths and thyroiditis.
The risk of thyroid cancer in later life appears to diminish with increasing age at time of exposure. Most risk estimates are based on studies in which radiation exposures occurred in children or teenagers. When adults are exposed, it has been difficult for epidemiologists to detect a statistically significant difference in the rates of thyroid disease above that of a similar but otherwise-unexposed group.
The risk can be mitigated by taking iodine supplements, raising the total amount of iodine in the body and, therefore, reducing uptake and retention in the face and chest and lowering the relative proportion of radioactive iodine. However, such supplements were not distributed to the population living nearest to the Chernobyl nuclear power plant after the disaster, though they were widely distributed to children in Poland.
Within the USA, the highest 131I fallout doses occurred during the 1950s and early 1960s to children having consumed fresh sources of milk contaminated as the result of above-ground testing of nuclear weapons. The National Cancer Institute provides additional information on the health effects from exposure to 131I in fallout, as well as individualized estimates, for those born before 1971, for each of the 3070 counties in the USA. The calculations are taken from data collected regarding fallout from the nuclear weapons tests conducted at the Nevada Test Site.
On 27 March 2011, the Massachusetts Department of Public Health reported that 131I was detected in very low concentrations in rainwater from samples collected in Massachusetts, USA, and that this likely originated from the Fukushima power plant. Farmers near the plant dumped raw milk, while testing in the United States found 0.8 pico-curies per liter of iodine-131 in a milk sample, but the radiation levels were 5,000 times lower than the FDA's "defined intervention level." The levels were expected to drop relatively quickly
Treatment and prevention
A common treatment method for preventing iodine-131 exposure is by saturating the thyroid with regular, non-radioactive iodine-127, as an iodide or iodate salt. Free elemental iodine should not be used for saturating the thyroid because it is a corrosive oxidant and therefore is toxic to ingest in the necessary quantities. The thyroid will absorb very little of the radioactive iodine-131 after it is saturated with non-radioactive iodide, thereby avoiding the damage caused by radiation from radioiodine. The most common method of treatment is to give potassium iodide to those at risk. The dosage for adults is 130 mg potassium iodide per day, given in one dose, or divided into portions of 65 mg twice a day. This is equivalent to 100 mg of iodine, and is about 700 times bigger than the nutritional dose of iodine, which is 0.150 mg per day (150 micrograms per day). See potassium iodide for more information on prevention of radioiodine absorption by the thyroid during nuclear accident, or for nuclear medical reasons. The FDA-approved dosing of potassium iodide for this purpose are as follows: infants less than 1 month old, 16 mg; children 1 month to 3 years, 32 mg; children 3 years to 18 years, 65 mg; adults 130 mg. However, some sources recommend alternative dosing regimens.
The ingestion of prophylaxis iodide and iodate is not without its dangers, There is reason for caution about taking potassium iodide or iodine supplements, as their unnecessary use can cause conditions such as the Jod-Basedow phenomena, and the Wolff-Chaikoff effect, trigger and/or worsen hyperthyroidism and hypothyroidism respectively, and ultimately cause temporary or even permanent thyroid conditions. It can also cause sialadenitis (an inflammation of the salivary gland), gastrointestinal disturbances, allergic reactions and rashes. Potassium iodide is also not recommended for those who have had an allergic reaction to iodine, and people with dermatitis herpetiformis and hypocomplementemic vasculitis, conditions that are linked to a risk of iodine sensitivity.
The use of a particular "iodine tablet" used in portable water purification has also been determined as somewhat effective at reducing radioiodine uptake. In a small study on human subjects who, for each of their 90-day trial, ingested four 20 milligram tetraglycine hydroperiodide (TGHP) water tablets, with each tablet releasing 8 milligrams (ppm) of free titratable iodine; it was found that the biological uptake of radioactive iodine in these human subjects dropped to and remained at a value of less than 2% the radioiodine uptake rate of that observed in control subjects who were fully exposed to radioiodine without treatment.
The administration of known goitrogen substances can also be used as a prophylaxis in reducing the bio-uptake of iodine, (whether it be the nutritional non-radioactive iodine-127 or radioactive iodine, radioiodine - most commonly iodine-131, as the body cannot discern between different iodine isotopes). Perchlorate ions, a common water contaminant in the USA due to the aerospace industry, has been shown to reduce iodine uptake and thus is classified as a goitrogen. Perchlorate ions are a competitive inhibitor of the process by which iodide, is actively deposited into thyroid follicular cells. Studies involving healthy adult volunteers determined that at levels above 0.007 milligrams per kilogram per day (mg/(kg·d)), perchlorate begins to temporarily inhibit the thyroid gland's ability to absorb iodine from the bloodstream ("iodide uptake inhibition", thus perchlorate is a known goitrogen). The reduction of the iodide pool by perchlorate has dual effects--reduction of excess hormone synthesis and hyperthyroidism, on the one hand, and reduction of thyroid inhibitor synthesis and hypothyroidism on the other. Perchlorate remains very useful as a single dose application in tests measuring the discharge of radioiodide accumulated in the thyroid as a result of many different disruptions in the further metabolism of iodide in the thyroid gland.
Treatment of thyrotoxicosis (including Graves' disease) with 600-2,000 mg potassium perchlorate (430-1,400 mg perchlorate) daily for periods of several months or longer was once common practice, particularly in Europe, and perchlorate use at lower doses to treat thryoid problems continues to this day. Although 400 mg of potassium perchlorate divided into four or five daily doses was used initially and found effective, higher doses were introduced when 400 mg/day was discovered not to control thyrotoxicosis in all subjects.
Current regimens for treatment of thyrotoxicosis (including Graves' disease), when a patient is exposed to additional sources of iodine, commonly include 500 mg potassium perchlorate twice per day for 18-40 days.
Prophylaxis with perchlorate-containing water at concentrations of 17 ppm, which corresponds to 0.5 mg/kg-day personal intake, if one is 70 kg and consumes two litres of water per day, was found to reduce baseline radioiodine uptake by 67% This is equivalent to ingesting a total of just 35 mg of perchlorate ions per day. In another related study where subjects drank just 1 litre of perchlorate-containing water per day at a concentration of 10 ppm, i.e. daily 10 mg of perchlorate ions were ingested, an average 38% reduction in the uptake of iodine was observed.
However, when the average perchlorate absorption in perchlorate plant workers subjected to the highest exposure has been estimated as approximately 0.5 mg/kg-day, as in the above paragraph, a 67% reduction of iodine uptake would be expected. Studies of chronically exposed workers though have thus far failed to detect any abnormalities of thyroid function, including the uptake of iodine. This may well be attributable to sufficient daily exposure or intake of healthy iodine-127 among the workers and the short 8-hr biological half life of perchlorate in the body.
To completely block the uptake of iodine-131 by the purposeful addition of perchlorate ions to a population's water supply, aiming at dosages of 0.5 mg/kg-day, or a water concentration of 17 ppm, would therefore be grossly inadequate at truly reducing radioiodine uptake. Perchlorate ion concentrations in a region's water supply would therefore need to be much higher, with at least a total dosage of 7.15 mg/kg of body weight per day needing to be aimed for, with this being achievable for most adults by consuming 2 liters of water per day with a water concentration of 250 mg/kg of water, or 250 ppm of perchlorate ions per liter; only at this level would perchlorate consumption offer adequate protection, and be truly beneficial to the population at preventing bioaccumulation when exposed to a radioiodine environment. This being entirely independent of the availability of iodate or iodide drugs.
The continual addition of perchlorate to the water supply would need to continue for no less than 80-90 days, beginning immediately after the initial release of radioiodine is detected; after 80-90 days have passed, released radioactive iodine-131 will have decayed to less than 0.1% of its initial quantity, and thus the danger from biouptake of iodine-131 is essentially over.
In the event of a radioiodine release, the ingestion of prophylaxis potassium iodide or iodate, if available, would rightly take precedence over perchlorate administration, and would be the first line of defense in protecting the population from a radioiodine release. However, in the event of a radioiodine release too massive and widespread to be controlled by the limited stock of iodide & iodate prophylaxis drugs, then the addition of perchlorate ions to the water supply, or distribution of perchlorate tablets, would serve as a cheap and efficacious second line of defense against carcinogenic radioiodine bioaccumulation.
The ingestion of goitrogen drugs is, much like potassium iodide, also not without its dangers, such as hypothyroidism. In all these cases however, despite the risks, the prophylaxis benefits of intervention with iodide, iodate, or perchlorate outweigh the serious cancer risk from radioiodine bioaccumulation in regions where radioiodine has sufficiently contaminatated the environment.
Medical use
It is used in nuclear medicine therapeutically and can also be seen with diagnostic scanners if it has been used therapeutically. Use of the 131I as iodide salt exploits the mechanism of absorption of iodine by the normal cells of the thyroid gland. Examples of its use in radiation therapy are those where tissue destruction is desired after iodine uptake by the tissue.
Major uses of 131I include the treatment of thyrotoxicosis (hyperthyroidism) and some types of thyroid cancer that absorb iodine. The 131I is thus used as direct radioisotope therapy to treat hyperthyroidism due to Graves' disease, and sometimes hyperactive thyroid nodules (abnormally active thyroid tissue that is not malignant). The therapeutic use of radioiodine to treat hyperthyroidism from Graves' disease was first reported by Saul Hertz in 1941.
The 131I isotope is also used as a radioactive label for certain radiopharmaceuticals that can be used for therapy, e.g. 131I-metaiodobenzylguanidine (131I-MIBG) for imaging and treating pheochromocytoma and neuroblastoma. In all of these therapeutic uses, 131I destroys tissue by short-range beta radiation. About 90% of its radiation damage to tissue is via beta radiation, and the rest occurs via its gamma radiation (at a longer distance from the radioisotope). It can be seen in diagnostic scans after its use as therapy, because 131I is also a gamma-emitter.
Because of the carcinogenicity of its beta radiation in the thyroid in small doses, I-131 is rarely used primarily or solely for diagnosis (although in the past this was more common due to this isotope's relative ease of production and low expense). Instead the more purely gamma-emitting radioiodine iodine-123 is used in diagnostic testing (nuclear medicine scan of the thyroid). The longer half-lived iodine-125 is also occasionally used when a longer half-life radioiodine is needed for diagnosis, and in brachytherapy treatment (isotope confined in small seed-like metal capsules), where the low-energy gamma radiation without a beta component makes iodine-125 useful. The other radioisotopes of iodine are never used in brachytherapy.
The use of 131I as a medical isotope has been blamed for a routine shipment of biosolids being rejected from crossing the Canada--U.S. border. Such material can enter the sewers directly from the medical facilities, or by being excreted by patients after a treatment.
Administration of therapeutic I-131
Typical therapeutic doses of I-131 are between 2220-7400 megabecquerels (MBq). Because of this high radioactivity and because the exposure of stomach tissue to beta radiation would be high near an undissolved capsule, I-131 is usually administered to human patients in a small amount of liquid. Administration of this liquid form is usually by straw which is used to slowly and carefully suck up the liquid from a shielded container. For administration to animals (for example, cats with hyperthyroidism), for practical reasons the isotope must be administered by injection.
Post-treatment isolation
IAEA International Basic Safety Standards recommend that patients are not discharged until the activity falls below 1100 MBq. ICRP advice states that "comforters and carers" of patients undergoing radionuclide therapy should be treated as members of the public for dose constraint purposes and any restrictions on the patient should be designed based on this principle.
Patients receiving I-131 radioiodine treatment may be warned not to have sexual intercourse for one month (or shorter, depending on dose given), and women told not to become pregnant for six months afterwards. "This is because a theoretical risk to a developing fetus exists, even though the amount of radioactivity retained may be small and there is no medical proof of an actual risk from radioiodine treatment. Such a precaution would essentially eliminate direct fetal exposure to radioactivity and markedly reduce the possibility of conception with sperm that might theoretically have been damaged by exposure to radioiodine." These guidelines vary from hospital to hospital and will depend on national legislation and guidance, as well as the dose of radiation given. Some also advise not to hug or hold children when the radiation is still high, and a one- or two- metre distance to others may be recommended.
I-131 will be eliminated from the body over the next several weeks after it is given. The majority of I-131 will be eliminated from the human body in 3-5 days, through natural decay, and through excretion in sweat and urine. Smaller amounts will continue to be released over the next several weeks, as the body processes thyroid hormones created with the I-131. For this reason, it is advised to regularly clean toilets, sinks, bed sheets and clothing used by the person who received the treatment. Patients may also be advised to wear slippers or socks at all times, and avoid prolonged close contact with others. This minimizes accidental exposure by family members, especially children. Use of a decontaminant specially made for radioactive iodine removal may be advised. The use of chlorine bleach solutions, or cleaners that contain chlorine bleach for cleanup, are not advised, since radioactive elemental iodine gas may be released. Airborne I-131 may cause a greater risk of second-hand exposure, spreading contamination over a wide area. Patient is advised if possible to stay in a room with a bathroom connected to it to limit unintended exposure to family members.
Many airports now have radiation detectors to detect the smuggling of radioactive materials that may be used in nuclear weapons manufacture. Patients should be warned that if they travel by air, they may trigger radiation detectors at airports up to 95 days after their treatment with 131I.
Industrial radioactive tracer uses
Used for the first time in 1951 to localize leaks in a drinking water supply system of Munich, Germany, iodine-131 became one of the most commonly used gamma-emitting industrial radioactive tracers, with applications in isotope hydrology and leak detection.
Since the late 1940s, radioactive tracers have been used by the oil industry. Tagged at the surface, water is then tracked downhole, using the appropriated gamma detector, to determine flows and detect underground leaks. I-131 has been the most widely used tagging isotope in an aqueous solution of sodium iodide. It is used to characterize the hydraulic fracturing fluid to help determine the injection profile and location of fractures created by hydraulic fracturing.
See also
- Iodine
- Isotopes of iodine
- Iodine in biology
- Iodide
- Potassium iodide
References
External links
- "ANL factsheet" (PDF). Archived from the original (PDF) on 14 June 2003.
- RadiologyInfo - The radiology information resource for patients: Radioiodine (I -131) Therapy
- Case Studies in Environmental Medicine: Radiation Exposure from Iodine 131
- Sensitivity of Personal Homeland Security Radiation Detectors to Medical Radionuclides and Implications for Counseling of Nuclear Medicine Patients
- NLM Hazardous Substances Databank - Iodine, Radioactive
Source of the article : Wikipedia
0 Comments